• IPR-803 and the uPAR–uPA Axis in Cancer Research

  2026-10-07

  IPR-803 is a small-molecule urokinase receptor inhibitor studied as a probe of uPAR–uPA signaling, tumor invasion, extracellular-matrix remodeling, and breast cancer metastasis. Published evidence supports direct target engagement and activity in selected preclinical models, but important uncertainties remain regarding selectivity, model generalizability, pancreatic cancer claims, and clinical relevance.

• tFUS, Nespas/SHP2, and Stroke Neuroinflammation

  2026-10-07

  A 2025 International Immunopharmacology study links low-intensity transcranial focused ultrasound with improved outcomes after experimental ischemic stroke and identifies the Nespas/miR-383-3p/SHP2 axis as a candidate regulator of microglial NLRP3 activation. The findings support a mechanistic framework for studying ultrasound-mediated neuroprotection, while remaining limited to preclinical rat and cell models.

• Podophyllotoxin and Autophagy in HCC Research

  2026-10-06

  A source-grounded overview distinguishing podophyllotoxin’s reported microtubule activity from the separate JXE-23 hepatocellular carcinoma study, with emphasis on autophagy interpretation, evidence strength, research applications, and translational limitations.

• Genistein in Mechanotransduction Research

  2026-10-06

  Genistein is a research compound relevant to kinase signaling, cell proliferation, and cancer biology. This overview compares vendor-reported pharmacology with findings from a 2024 study showing that compression-induced autophagy depends primarily on cytoskeletal microfilaments, while emphasizing evidence limits and the need to avoid equating mechanotransduction findings with direct evidence for genistein.

• Lapatinib in EGFR and HER2 Cancer Research

  2026-10-05

  Lapatinib, also known as GW572016, is a reversible EGFR and HER2 kinase inhibitor used in targeted cancer therapy research. This overview examines its mechanistic context, supplier-reported biochemical activity, and findings from a 2026 study of lapatinib plus telatinib in HER2-negative triple-negative breast cancer cells, while emphasizing evidence limits and translational boundaries.

• Gefitinib (ZD1839): Reading EGFR Biology in Context

  2026-10-05

  Gefitinib (ZD1839) is a useful pharmacological lens for studying EGFR signaling pathway inhibition, but its biological meaning depends on tissue context. This article connects cancer-cell mechanisms with new evidence on blue-light-associated skin barrier injury while emphasizing causal interpretation, evidence strength, and translational limits.

• Dicoumarol, IRE1α, and ER Stress Liver Injury

  2026-10-04

  A 2025 Life Sciences study combined molecular docking, an XBP1s reporter system, cell models, and mouse injury models to identify dicoumarol as a candidate inhibitor of IRE1α signaling. The findings support a screening framework for connecting pathway-level modulation with protection from tunicamycin- and carbon tetrachloride-associated acute liver injury, while leaving important questions about mechanism, selectivity, and clinical relevance unresolved.

• p-Cresyl Sulfate: Research Context and Evidence

  2026-10-03

  This overview examines p-Cresyl sulfate, also known as p-tolyl hydrogen sulfate, as a protein-bound uremic retention solute and research biomarker. It compares recent preclinical evidence in biliary epithelial injury with supplier-described cardiovascular applications, emphasizing provenance, translational limits, and unanswered questions.

• Ganetespib (STA-9090) Experimental Workflows

  2026-10-02

  Ganetespib (STA-9090) combines potent N-terminal Hsp90 inhibition with a practical framework for dose-response, client-protein, and tumor-model studies. This guide translates its cancer research utility into reproducible workflows while showing how the reference study’s compartment-specific secretion assays can sharpen mechanistic interpretation.

• tFUS, SHP2, and NLRP3 After Ischemic Stroke

  2026-10-01

  This study identifies the Nespas/miR-383-3p/SHP2 axis as a mechanistic link between low-intensity transcranial focused ultrasound stimulation and reduced NLRP3-associated neuroinflammation after ischemic stroke. Its combination of an MCAO rat model, microglial OGD/R experiments, RNA sequencing, and targeted pathway perturbation provides a framework for testing how neuromodulation affects inflammatory signaling.

• TPA as a Causal Probe of ERK and Autophagy

  2026-10-01

  Discover how 12-O-tetradecanoyl phorbol-13-acetate (TPA) can function not only as an ERK/MAPK activator, but also as a causal perturbation tool for dissecting ERK/FoxO3a regulation and impaired autophagic flux. This guide translates recent mechanistic findings into practical assay and interpretation decisions.

• AG-490 for JAK2/STAT6 Macrophage Assays

  2026-09-30

  AG-490, also called Tyrphostin B42, provides a practical pharmacologic probe for testing whether exosome-driven macrophage polarization depends on JAK-linked signaling. This workflow emphasizes dose separation, pathway readouts, solvent controls, and interpretation limits in hepatocellular carcinoma models.

• APOE, Macrophage Polarization, and PTC Progression

  2026-09-30

  The reference study identifies APOE as a molecular link between papillary thyroid carcinoma cells, PI3K/Akt/NF-κB signaling, and M2-like macrophage polarization. Its integrated tissue, co-culture, and xenograft evidence suggests that APOE contributes to PTC progression and offers a framework for studying tumor–macrophage communication.

• Clozapine in Schizophrenia Circuit Research

  2026-09-29

  Clozapine provides a pharmacological benchmark for separating broad receptor effects from targeted prelimbic-cortex neuromodulation. This workflow connects ERK1/2 signaling activation, GABRE-focused assays, behavioral phenotyping, and hepatotoxicity studies while preserving clear experimental boundaries.

• SU 5402 Workflows for RTK and Neuron Studies

  2026-09-29

  SU 5402 supports quantitative interrogation of VEGFR2, FGFR, and PDGFR signaling in cancer models, while its use in human sensory-neuron systems is best positioned as an exploratory pathway perturbation. This guide connects phospho-signaling, cell-cycle, apoptosis, and HSV-1 latency readouts with practical controls and troubleshooting safeguards.

7911 records 1/528 page Next 12345 下5页 Last page